Everett Harris & Co. CA raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 813,919 shares of the company’s stock after purchasing an additional 17,645 shares during the period. Johnson & Johnson accounts for 2.6% of Everett Harris & Co. CA’s portfolio, making the stock its 10th largest position. Everett Harris & Co. CA’s holdings in Johnson & Johnson were worth $105,305,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Bogart Wealth LLC grew its position in Johnson & Johnson by 4.4% in the 3rd quarter. Bogart Wealth LLC now owns 7,673 shares of the company’s stock worth $993,000 after purchasing an additional 324 shares during the period. Financial Advisory Service Inc. grew its position in Johnson & Johnson by 0.6% in the 3rd quarter. Financial Advisory Service Inc. now owns 13,902 shares of the company’s stock worth $1,799,000 after purchasing an additional 85 shares during the period. Corient Capital Partners LLC grew its position in Johnson & Johnson by 1.6% in the 3rd quarter. Corient Capital Partners LLC now owns 48,865 shares of the company’s stock worth $6,322,000 after purchasing an additional 758 shares during the period. Banco Santander S.A. grew its position in Johnson & Johnson by 8.3% in the 3rd quarter. Banco Santander S.A. now owns 277,516 shares of the company’s stock worth $35,905,000 after purchasing an additional 21,335 shares during the period. Finally, Vaughan Nelson Investment Management L.P. grew its position in Johnson & Johnson by 40.9% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 192,825 shares of the company’s stock worth $24,948,000 after purchasing an additional 55,950 shares during the period. 72.21% of the stock is owned by institutional investors.
JNJ has been the subject of a number of research analyst reports. Wells Fargo & Co cut their target price on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, October 16th. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Friday, October 11th. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $151.64.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.05 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 8.66 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What is meant by holder of record?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.